Stocksigma LogoStocksigma Logo

Gland Pharma Approves $21M US Investment and Board Changes

Gland Pharma鈥檚 board approved a USD 21 million cash investment in wholly owned subsidiary Gland Pharma USA Inc

Gland Pharma Approves $21M US Investment and Board Changes

Gland Pharma Ltd 路 Change in Management 路 01 Oct 2026, 9:24 pm

Gland Pharma Approves $21M US Investment and Board Changes Gland Pharma鈥檚 board approved a USD 21 million cash investment in wholly owned subsidiary Gland Pharma USA Inc. to acquire a 60% stake in US-based Novelstar Pharma Inc. by 31st Oct'26, expanding its US market footprint. Fosun Pharma USA Inc. will hold the remaining 40% in Novelstar. Additionally, Non-Executive Non-Independent Director Wenjie Zhang resigned effective 1st Oct'26 due to preoccupations, and Xingli Wang, President of Fosun Pharma, was appointed as an Additional Director (Non-Executive Non-Independent) on the same date.

Original exchange filing (PDF)

More announcements from Gland Pharma Ltd

All Gland Pharma Ltd announcements